Passkey Therapeutics Revenue and Competitors

Boston, MA USA

Location

$22M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Passkey Therapeutics's estimated annual revenue is currently $3.4M per year.(i)
  • Passkey Therapeutics's estimated revenue per employee is $155,000
  • Passkey Therapeutics's total funding is $22M.

Employee Data

  • Passkey Therapeutics has 22 Employees.(i)
  • Passkey Therapeutics grew their employee count by 83% last year.

Passkey Therapeutics's People

NameTitleEmail/Phone
1
Chief Technology Officer | Co-FounderReveal Email/Phone
2
Co-Founder, Chief Technology OfficerReveal Email/Phone
3
Co-founder & SVP, Computational ChemistryReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
VP, Medicinal ChemistryReveal Email/Phone
6
Associate Director, ImmunologyReveal Email/Phone
7
Senior Director FinanceReveal Email/Phone
8
Senior Director, BiologyReveal Email/Phone
9
Senior Director, FinanceReveal Email/Phone
10
Business Operations ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Passkey Therapeutics?

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics or SMThs, designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions.

keywords:N/A

$22M

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

83%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.1M22-8%$161M
#2
$3.5M22-41%N/A
#3
$3.1M22N/AN/A
#4
$2.8M220%N/A
#5
$2.2M22-8%N/A